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Abstract
Historically, administration of dacarbazine to sarcoma patients was limited by frequent treat-ment-related nausea/
vomiting and neutropenia. These toxicities are now largely preventable with contemporary antiemetics and growth 
factor support. In this single-arm, phase II study, dacarbazine 850 mg/m2 was given on day 1 of each 3-week cycle until 
disease progression or intolerance with prophylactic serotonin-3 receptor, neurokinin-1 antagonists, corticosteroids, 
and pegfilgrastim. Coprimary endpoints included clinical benefit rate (CBR), and any grade of nausea/vomiting and/or 
grade 3–4 neutropenia. With a sample size of 80 patients, >24 patients with clinical benefit would indicate that the CBR 
exceeds the historical (<20%) [Power 0.80; alpha 0.05]. In addition, we hypothesized that the rates of nausea/vomiting 
would be 27% and grade 3–4 neutropenia would be 1% (historical: 90% and 36%, respectively) [power 0.95; alpha 0.05]. 
The CBR was 30% (24 patients: PR-2 and stable-22). The rate of nausea/vomiting was 37.5% (31 patients) and grades 3–4 
neutropenia was 10% (8 patients). Median time-to-progression was 8.1 weeks (95% CI 8–9.7) and median overall survival 
was 35.8 weeks (95% CI 26.2–55.4). PET scans demonstrated no association with response. Modern prophylactic anti-
emetics and pegfilgrastim given with dacarbazine reduced the rates of treatment related nausea/vomiting and serious 
neutropenia.
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Soft tissue sarcomas (STS) and bone sarcomas are a rare 
group of heterogeneous tumors of mesenchymal cell origin. 
Currently, over 150 subtypes of sarcoma have been identi-
fied. Sarcomas have an expected incidence of ~18,000 in 
2020 in the US1 and account for approximately 1% of all 
cancer diagnoses. For disease that is localized, surgery with 
or without radiation therapy is the standard approach. For 
patients with metastatic disease, systemic chemotherapy is 
the mainstay of care with a median overall survival (OS) of 
20 months.2–6 In the 1970’s, dacarbazine was one of the first 
chemotherapeutic agents found to have anti-tumor activity 
in the treatment of metastatic sarcoma.7 In an era without 
potent prophylactic anti-emetics and leukocyte growth fac-
tors, the effectiveness of dacarbazine was limited by treat-
ment-related nausea/vomiting, which occurred in 90% of 
patients, and grade 3–4 neutropenia, which occurred in 36% 
of patients. These toxicities frequently resulted in early dis-
continuation of the drug even before first tumor response 
assessment or disease progression. Improvement in response 
rates were seen when dacarbazine was combined with ifos-
famide and doxorubicin8; however, randomized trials were 
not clearly or consistently able to document an improve-
ment in OS with multi-agent chemotherapy.
In the late 1990s, the use of dacarbazine fell out of favor 
among many investigators with the prevailing belief that it 
was less effective than either ifosfamide or doxorubicin, 
and caused significant toxicity, namely nausea, vomiting, 
and myelosuppresion, which at the time had few effective 
prevention strategies. In current practice, when dacarbazine 
is utilized in the first line setting, it is often given in combi-
nation with anthracyclines in patients with a sensitive histo-
logic subtype, or in instances where the use of ifosfamide is 
contraindicated. In later-line settings, dacarbazine is uti-
lized as a single agent. In 2007, a retrospective analysis of 
single-agent dacarbazine given in the second/third-line set-
ting to 40 patients with refractory disease demonstrated a 
clinical benefit rate (CBR) of 20% and a median progres-
sion-free survival (PFS) of 2 months.9
In recent years, dacarbazine has been used as a reference 
arm for new investigational treatments in clinical trials of 
patients with anthracycline-refractory disease, such as in 
the phase III evaluations of trabectedin10 or eribulin.11 
Across these two trials of nearly 1000 patients, dacarbazine 
resulted in objective response rates of 5%–7%, median PFS 
of 1.5–2.6 months, and median OS of 11.5–12.9 months. 
The proportion of patients who were given dacarbazine that 
experienced nausea/vomiting was 47%–49%, and grade 
3–4 neutropenia was 16%–22%. The antiemetics adminis-
tered before dacarbazine included only corticosteroids, and 
prophylactic leukocyte growth factors were not routinely 
used.
In this trial, we hypothesized that administration of 
potent prophylactic anti-emetics and growth factors with 
dacarbazine would markedly reduce the proportion of 
patients who experience treatment-related nausea, vomit-
ing, and neutropenia and would result in a CBR better than 
historical data.
Materials and methods
This was a single-arm, single-institution, prospective phase 
II trial (NCT00802880) of patients 18 years of age or older 
with a histologically proven diagnosis of metastatic or 
locally recurrent STS or bone sarcoma that had progressed 
after one or more prior chemotherapy regimens (excluding 
adjuvant chemotherapy). Patients were required to have 
measurable disease by CT, FDG-avid disease (SUVmax ⩾ 3) 
on FDG-PET/CT, Eastern Cooperative Oncology Group 
(ECOG) performance status of 0–2 and adequate marrow 
and organ function (ANC ⩾1000/µL, hemoglobin ⩾8 g/dL, 
platelets ⩾100,000/dL, serum creatinine ⩽2.0 mg/dL, total 
bilirubin ⩽2.0, and AST or ALT <3× ULN). Patients were 
ineligible if they had chemotherapy or radiation within the 
last 21 days or if any investigational agent had been given 
within the last 30 days. The study was conducted at 
Washington University in St. Louis and was approved by 
the Institutional Review Board and Radioactive Drug 
Research Committee, as well as the Protocol Review and 
Monitoring Committee of the Siteman Cancer Center. All 
patients provided written informed consent.
Baseline assessments, including medical history, physi-
cal examination, vital signs, clinical laboratory tests includ-
ing complete blood count and metabolic profile, and baseline 
imaging including CT and FDG-PET/CT (skull vertex to 
thighs), were performed within 21 days of Cycle 1.
Dacarbazine was administered intravenously (IV) at a 
dose of 850 mg/m2 over 1 h on day 1 of each 3-week cycle. 
The prophylactic anti-emetic regimen given IV prior to 
dacarbazine included three drugs: palonosetron (0.25 mg) 
or ondansetron (32 mg), aprepitant (150 mg), and dexa-
methasone (20 mg). Pegfilgrastim (6 mg subcutaneously) 
was administered on day 2 of each cycle. Treatment contin-
ued until disease progression, unacceptable toxicity, or 
withdrawal of consent. On treatment, assessments included 
physical examination and laboratory studies on day 1 of 
each cycle, and tumor response assessments every three 
cycles.
Tumor response was assessed on CT of the chest, abdo-
men, and pelvis by RECIST 1.012 and metabolic response 
was assessed on FDG-PET/CT by a modification of the 
EORTC criteria.13 These imaging assessments were 
obtained at baseline, and planned on days 12–21 after the 
start of cycle 3 and every three cycles thereafter unless clin-
ical progression occurred earlier (Schema in Figure 1). 
Disease progression was defined based on RECIST. FDG-
PET/CT was utilized for metabolic response assessment 
using the SUVmax within metastatic tumor sites. Up to a 
maximum of three lesions having the greatest FDG uptake 
were identified as target lesions on baseline PET. If more 
Van Tine et al. 3
than one target lesion was identified, the average change in 
SUVmax was used to determine the metabolic response.
Safety was assessed by monitoring for treatment-emer-
gent adverse events (TEAEs) and graded using NCI 
CTCAE version 3.0. Dose reductions by 15% of the origi-
nal dacarbazine dose (850 mg/m2) were required for grade 
3 and 4 neutropenia, thrombocytopenia, nausea/emesis, 
diarrhea, hepatic and renal toxicity, hypocalcemia, or 
hypersensitivity. A maximum of three dose reductions were 
permissible, after which the drug was discontinued.
Co-primary endpoints included CBR (the proportion of 
patients with complete or partial response [PR] or stable 
disease [SD]), and the frequency of any grade of nausea/
vomiting or grade 3–4 neutropenia. When our trial was 
developed, the historical CBR with dacarbazine monother-
apy was reported to be ⩽20%.9 Data from the phase III 
trials of eribulin or trabectedin versus dacarbazine were 
reported several years later.10,11 With a sample size of 80 
patients, ⩾24 patients with clinical benefit resulted in a 
CBR that exceeded the historical rate (20%) [power 0.80; 
alpha 0.05]. Also, a sample size of 80 patients was able to 
detect a reduction in the rates of any grade nausea/vomiting 
from the historical of 90% to 27% and in the rates of grade 
3–4 neutropenia from the historical of 36% to 1% (power 
0.95; alpha 0.05).
Kaplan-Meier models were used to estimate median 
time-to-progression (TTP: time from study enrollment to 
tumor progression) and median OS (time from the start of 
treatment to death from any cause) with 95% confidence 
intervals. The log-rank test was used to compare TTP and 
OS among categories of each response endpoint.
Results
Patients
From March 2009 to December 2014, 80 patients were 
enrolled. Baseline characteristics are listed in Table 1. The 
majority of patients had ECOG performance scores of 0–1. 
All but one patient had metastatic disease, and more than 
Figure 1. Schema of the phase II dacarbazine trial. Baseline assessments included medical history, physical examination, vital signs, 
clinical laboratory tests including complete blood count and metabolic profile, and baseline imaging including CT and FDG-PET/CT 
(skull vertex to thighs), were performed within 21 days of cycle 1.
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half of patients had received three or greater lines of prior 
systemic therapy. The most common histologic subtypes 
were leiomyosarcoma and liposarcoma. The number of STS 
tumors was 75, the number of bone tumors was 5 (Table 2).
Treatment administered
Patients received a median of three cycles of dacarbazine 
(range 1–36). Seven of the 80 patients received 10 or more 
cycles. The most common reason for therapy discontinua-
tion was disease progression (78%). Other reasons 
included drug toxicity, patient noncompliance, and patient 
death.
Primary end points
The CBR was 30% (24 of 80 patients). Two patients had a 
PR (3%), and 22 patients had SD (28%). The overall num-
ber of patients with PD was 56 patients (55%): 30 had PD 
by RECIST and 26 were considered to have PD because 
they did not undergo a tumor response assessment, as CT 
and PET/CT cans were not obtained per protocol on patients 
who progressed or died before week 9 and thus were 
deemed to be off trial. The two patients with objective 
tumor response had leiomyosarcoma.
The rate of any grade nausea/vomiting was 37.5% (31 
patients) and grade 3–4 neutropenia was 10% (8 patients).
Secondary efficacy endpoints
Metabolic tumor response was assessed with FDG-PET/CT 
performed at baseline and after every three cycles of treat-
ment. The numbers of patients evaluable for metabolic 
response at baseline and after cycles 3, 6, 9, and 12 were 51, 
50, 20, 7, and 5, respectively; 29 patients were not evalua-
ble because a second FDG/PET scan was not performed, 
most often because of early progression. Of the 50 evalua-
ble patients, partial metabolic response (PMR) occurred in 
4, stable metabolic disease (SMD) in 13 and progressive 
metabolic disease (PMD) in 34. Tumor metabolic response 
rates were significantly correlated to the anatomic response 
rate in 49 patients as shown in Table 3.
Seventy-nine patients were included in the OS analysis 
as one patient withdrew consent: the median OS was 
8.09 months (95% CI 5.72–12.7; Figure 2(a)). Median TTP 
was 2.7 months (95% CI 1.84–2.3; Figure 2(b)). OS and 
TTP were reported by best anatomic response (Figure 2(c) 
and (d), respectively). OS and TTP were also reported by 
best metabolic response (Figure 2(e) and (f), respectively).
Mean SUVs were compared at baseline and at cycle 3 in 
patients with PR + SD versus those with PD. At baseline 
there was no significant difference in the mean SUV for 
those with PD versus PR + SD, but at cycle 3 there was a 
significant difference in the SUV between these two groups 
(p = 0.01; Figure 3).
In the 51 patients who received a PET at cycle 3, the 
responses of PD versus PR + SD were correlated to OS 
(Figure 4(a)) and TTP (Figure 4(b)).
Adverse events
The most frequent AEs (Table 4) of any grade included ane-
mia (72%), lymphopenia (67%), and thromobocytopenia 
Table 1. Patient characteristics.
Characteristic No. %
Sex
 Female 40 50
 Male 40 50
Age, years
 Median 53  
 Range 20–83  
ECOG performance status
 0 45 56
 1 32 40
 2 3 3
Site of primary
 Extremity 37 46
 Retroperitoneum/uterus 27 33
 Head and neck 6 7
 Other 10 12
Extent of disease
 Locally advanced 1 1
 Metastatic 79 98
 Pulmonary metastases only 11 13
 Liver metastases 18 22
No. of previous therapies
 1 1 1
 2 28 35
 3 22 27
 >3 29 36




Malignant fibrous histiocytoma 7
Peripheral nerve sheath 6
Osteosarcoma 5







Sarcoma – spindle cell 2
High grade undifferentiated 2
Endometrial stromal cell 1
Adenocarcinoma 1
Desmoid/small round cell tumor 1
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Table 3. Correlation of metabolic to anatomic responses.




Total Cohen’s Kappa Fisher exact 
test p value
PR + SD 13 9 22  
PD 3 24 27  
Total 16 33 49 0.49 (0.25–0.73) 0.0005876
Figure 2. Response data. Demonstrates overall survival (a), time to progression (b), times to progression by best anatomic (c) or 
best metabolic (d) response, as well as overall survival by best anatomic response (e), and best metabolic response (f).
PD: progressive disease; PMD: partial metabolic response; PMR: partial metabolic response; PR: partial response; SD: stable disease; SMD: stable 
metabolic response.
6 Rare Tumors
(35%). The most frequent grade 3–4 AEs included lympho-
penia (26%) and fatigue (12%).
Discussion
In this trial, we administered a prophylactic modern 
three-drug anti-emetic regimen and pegfilgrastim with 
each cycle of dacarbazine. Using this approach, the rates 
of treatment-related nausea/vomiting (37.5%) and grade 
3–4 neutropenia (10%) were lower than historical and 
contemporary reports of dacarbazine monotherapy. 
Historical reports conducted in an era of poorly effective 
anti-emetics and lack of clinically available growth fac-
tors showed that the rate of dacarbazine-related nausea/
vomiting was 90% and grade 3–4 neutropenia was 36%.9 
Contemporary reports used only corticosteroids as the 
anti-emetic regimen and no prophylactic growth factors 
and showed rates of nausea/vomiting and grade 3–4 neu-
tropenia were 47%–49% and 16%–22%, respectively.10,11 
Based on the results of our trial, modern multi-agent anti-
emetics and leukocyte growth factors should be prophy-
lactically administered with dacarabazine to reduce the 
risk of these AEs.
When our trial was developed, historical reports showed 
that the CBR with dacarbazine monotherapy was 20%.9 
We showed that the CBR assessed by RECIST with dacar-
bazine was 30%. Clinical benefit (PR or SD) occurred in 
24 of 80 patients, meeting the pre-specified threshold of 
superiority of the CBR compared to historical (20%) 
reports.9 The patients who had clinical benefit that lasted 
over 6 months had varying histologic subtypes, including 
fibrosarcoma, malignant fibrous histiocytoma, and leio-
myosarcoma. All five patients with osteosarcoma experi-
enced disease progression as the best response to 
dacarbazine, suggesting a lack of efficacy of dacarbazine 
in this subtype.
After our trial was initiated, the phase III trials of tra-
bectedin or eribulin versus dacarbazine were reported.10,11 
Interestingly, the CBR of dacarbazine in these reports 
were 42%–53%, higher than historical reports and higher 
than we observed in this trial. Differences in tumor char-
acteristics and prior therapy likely contributed to these 
observations. For example, all patients in the trabectedin 
and eribulin trials had leiomyosarcoma and liposarcoma, 
subtypes know to be chemosensitive; whereas, in our trial, 
only 29 of 80 patients (36%) had these subtypes.
Figure 3. Demonstrates mean PET SUV from baseline to cycle 
3 by response.
Figure 4. (a) Mean OS and (b) TTP based on metabolic responses at cycle 3.
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In the dacarbazine arms of the phase III trabectedin or 
eribulin versus dacarbazine trials, the ORRs were 5%–7%, 
the median PFS was 1.5–2.6 months, and the median OS 
was 11.5–12.9 months.10,11 In our trial, the ORR with dacar-
bazine was 3%, the median TTP was 8.14 weeks and median 
OS was 35.8 weeks. Given the differences in histologic 
subtypes and prior therapy, it is surprising that the ORR and 
TTP or PFS were similar across these three trials.
This is the first report that describes the metabolic tumor 
response to dacarbazine in patients with STS. The role of 
FDG-PET/CT in predicting response in sarcoma is cur-
rently not clear.14–16 Table 3 illustrates the significant cor-
relation between anatomic and metabolic responses in the 
evaluable patients. Our data showed no significant differ-
ence in anatomic responses based on mean SUV at base-
line, but did show a significant difference at cycle 3; where 
those with PR + SD had a lower mean SUV at this time 
point as compared to those with PD. The difference in over-
all survival based on those with PMD versus those with 
PMR + SMD at cycle 3 was not significant; however, TTP 
was trending toward significance in those with PMR + SMD 
at cycle 3 versus those with PMD. Taken together, these 
data suggest that FDG-PET/CT may have some utility as a 
predictive tool for response, but larger scale studies are 
needed.
While our trial included a large sample size for a phase 
2 trial, there was no parallel control arm. Additionally, his-
tologic subtypes were heterogeneous, as was number of 
lines of prior therapy, which makes generalizability of these 
data difficult. Procedures and grading and assessment sys-
tems for AEs and tumor response in our trial varied from 
the historical report due to the large gap in time between the 
two trials.9 However, these issues were similar to those 
used in contemporary reports.10,11 Doses of dacarbazine 
Table 4. Adverse events reported in ⩾10% of participants.
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Constitutional
 Edema 14 7 1 0 0
 Fatigue 13 10 10 0 0
 Anorexia 6 5 1 0 0
Gastrointestinal
 Constipation 13 5 1 0 0
 Diarrhea 11 2 0 1 0
 Nausea 11 2 5 0 0
 Vomiting 7 2 3 0 0
Hematologic
 Hemoglobin 29 18 9 2 0
 Leukocytes (WBC) 12 7 4 1 0
 Lymphopenia 11 22 18 3 0
 Neutrophils (ANC) 4 3 4 4 0
 Platelets 18 6 4 6 0
Hepatic function
 Alkaline phosphatase 13 4 2 0 0
 SGOT (AST) 12 0 2 2 0
 SGPT (ALT) 11 2 1 1 0
Metabolic/laboratory
 Low albumin 15 10 2 0 0
 Hypocalcemia 19 9 0 1 0
 Hyperglycemia 8 9 5 0 0
 Hypokalemia 8 0 3 1 0
 Hyponatremia 16 2 3 0 0
Pain
 Abdominal 4 3 2 1 0
 Bone 14 4 5 0 0
 Disease pain 4 6 7 0 0
Pulmonary
 Cough 7 5 0 0 0
 Dyspnea (SOB) 6 6 6 0 1
Renal/genito-urinary
 Creatinine 7 4 0 0 0
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used across the trials varied, although the range of doses 
were all within what is clinically relevant to practice 
patterns.
Conclusions
We conclude from our trial that a modern prophylactic three-
drug anti-emetic regimen and pegfilgrastim given with dac-
arbazine reduced the rates of treatment-related nausea/
vomiting and serious neutropenia. The CBR was modestly 
improved. Prophylactic, potent anti-emetics, and pegfil-
grastim should be routinely administered with dacarbazine.
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